Document is current
Any future updates will be listed below
-
Authors
Nieder, Carsten
Aanes, Siv Gyda
Stanisavljevic, Luka
Mannsåker, Bård
-
Funding
Funding for this research was provided by:
Open access funding provided by UiT The Arctic University of Norway
UiT The Arctic University of Norway
- License Information
-
More Information
Article History
Received: 11 June 2024
Accepted: 17 September 2024
First Online: 27 September 2024
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. As a retrospective quality of care analysis, no approval from the Regional Committee for Medical Research Ethics Northern Norway (REK North, Tromsø, Norway) was necessary. The study was performed in the context of our already institutional review board (IRB)-approved longitudinal monitoring of NSCLC management. This research project was carried out according to our institutions’ guidelines and with permission to access the patients’ data. Written informed consent was received from all patients.
: Not applicable.
: S.G.A. has received lecture fees from Merck, BMS, Astra Zeneca and Pfizer. B.M. has received lecture fees from BMS, Astra Zeneca, Gilead, Roche, Novartis and Pfizer. L.S. has received lecture fees from Pfizer, MSD, Janssen and Ipsen. LS har received consulting fees from MSD. C.N.: no conflict of interests.
